The global transcatheter heart valve replacement (THVR) market was valued at USD 4.04 billion in 2018 and is expected to grow significantly, reaching around USD 10.34 billion by 2026. This reflects a strong compound annual growth rate (CAGR) of 12.5% over the forecast period. Among all regions, North America led the market, holding a dominant 40.1% share in 2018.

Heart valve diseases, including valve regurgitation, are becoming one of the major causes of death worldwide. In fact, the American Heart Association reports that bicuspid aortic valve defects affect approximately 13.7 out of every 1,000 people in the U.S. This growing burden of heart valve disorders, along with proactive efforts from governments to support advanced treatment options, has significantly increased the demand for transcatheter heart valve replacement. Governments have also been giving the green light for new product launches, helping to speed up innovation and availability in this field. One of the biggest advantages of transcatheter technology is that it offers a less invasive alternative to traditional surgical valve replacement, making it a preferred option for many patients and physicians.

According to the European Heart Journal article titled “The Year in Cardiology 2017 - Valvular Heart Disease,” the total number of aortic valve replacement procedures worldwide was expected to reach 850,000 by 2020. Additionally, the rising rates of obesity and the growing incidence of congenital heart diseases are further boosting demand for transcatheter heart valve procedures.

Request a Free Sample PDF:

 https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/transcatheter-heart-valve-replacement-market-105572

Market Trend:

The Transcatheter Heart Valve Replacement (THVR) Market is witnessing a significant shift towards minimally invasive procedures as patients and physicians increasingly prefer valve replacement techniques that reduce recovery time and surgical complications. The rise in cardiovascular disorders, especially among the aging population, is pushing the demand for advanced heart valve therapies. Innovations such as next-generation transcatheter valves with better durability and positioning accuracy are also driving adoption.

Market Segmentation:

The Transcatheter Heart Valve Replacement (THVR) Market can be segmented based on procedure type, valve type, end-user, and region.

By procedure type, the market is divided into transapical implantation and transfemoral implantation. Among these, the transfemoral approach dominates due to its less invasive nature and shorter recovery times. As technology advances, the preference for this segment continues to grow among both patients and healthcare providers.

In terms of valve type, the market is categorized into balloon-expandable valves and self-expanding valves. Balloon-expandable valves are currently leading due to their excellent clinical performance and growing clinical data supporting long-term durability. However, self-expanding valves are gaining traction in complex anatomies and high-risk cases.

Based on end-user, hospitals, cardiac centers, and ambulatory surgical centers are key segments. Hospitals hold the largest share of the Transcatheter Heart Valve Replacement (THVR) Market due to their infrastructure, trained personnel, and wide availability of heart team support for complex cases.

List Of Key Companies Profiled:

• Edwards Lifesciences Corporation
• Abbott
• Medtronic
• LivaNova PLC
• Boston Scientific Corporation
• CryoLife, Inc.
• Micro Interventional Devices, Inc.
• Others

Market Growth:

The Transcatheter Heart Valve Replacement (THVR) Market is growing rapidly, fueled by the rising prevalence of aortic stenosis and other valvular diseases. Increased approvals for transcatheter devices, growing awareness among patients, and improved access to advanced cardiovascular care are some of the primary factors contributing to this growth. Furthermore, ongoing clinical trials and the expansion of indications for THVR in low-risk patient groups are expected to accelerate market expansion over the coming years.

Restraining Factors:

Despite strong momentum, the Transcatheter Heart Valve Replacement (THVR) Market faces a few restraints. High procedure costs and limited reimbursement in developing regions can deter widespread adoption. Additionally, risks associated with device malpositioning, valve degeneration, and procedural complications can hinder market acceptance in some patient groups. A lack of skilled professionals in emerging economies also poses a challenge to the market's growth potential.

Regional Analysis:

Regionally, North America leads the Transcatheter Heart Valve Replacement (THVR) Market due to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and early adoption of innovative medical technologies. Europe follows closely, with strong government support for cardiac procedures and high healthcare spending. Meanwhile, the Asia-Pacific region is emerging as a promising market thanks to growing awareness, increasing healthcare investments, and a rapidly aging population. Countries like China and India are expected to witness significant growth in THVR procedures over the next few years.

Key Industry Developments:

In September 2019, Medtronic launched its Evolut PRO+ system in the U.S., offering a new option for transcatheter aortic valve replacement (TAVR). This advanced system is designed to improve valve performance and make the procedure even safer and more effective for patients.

In November 2019, Edwards Lifesciences received CE Mark approval for its SAPIEN 3 valve, allowing it to be used for patients with aortic stenosis who are at lower risk for open-heart surgery. This approval means more patients in Europe can benefit from a less invasive treatment option.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free)

APAC: +91 744 740 1245

Email: [email protected]